脑肿瘤分子影像:[18F]FDG之外的SSTR PET与氨基酸PET
本文为AJR分子影像专刊综述,总结[18F]FDG、SSTR靶向药物、氨基酸示踪剂及新兴示踪剂在脑肿瘤PET评估中的临床作用。文章强调SSTR PET对脑膜瘤、氨基酸PET对胶质瘤及脑转移瘤的增益价值,并讨论诊疗一体化等精准神经肿瘤应用。
要点
- SSTR PET对脑膜瘤具有高肿瘤-背景对比度,有助于放疗计划与疗效评估。
- 氨基酸PET有助于区分胶质瘤及脑转移瘤的肿瘤进展与治疗相关改变。
- [18F]FDG因灰质生理性高摄取而应用受限,需结合靶向示踪剂解读。
核心结论
- SSTR靶向PET(含DOTATATE PET)通过高肿瘤-背景对比度显著影响脑膜瘤评估,并可用于副神经节瘤、嗅神经母细胞瘤及其他SSTR阳性肿瘤。
- 氨基酸PET可改善胶质瘤和脑转移瘤的评估,尤其在区分肿瘤进展与治疗相关改变方面具有价值。
- 靶向激素受体、缺氧、肿瘤新生血管及肿瘤微环境的新兴示踪剂正在扩展PET可提供的生物学信息。
研究设计与样本
- 本文为AJR分子影像专刊综述,总结[18F]FDG、SSTR靶向药物、氨基酸示踪剂及新兴示踪剂在脑肿瘤PET评估中的当前临床作用。
- 文章梳理各类示踪剂的优势与局限,并探讨将靶向PET整合入精准神经肿瘤学的演进应用。
临床应用与阅片要点
- SSTR靶向PET可用于脑膜瘤放疗计划制定、疗效评估及肽受体放射性核素治疗的患者筛选。
- 氨基酸PET可作为胶质瘤和脑转移瘤中肿瘤进展与治疗相关改变鉴别的补充手段。
- [18F]FDG PET受灰质生理性高摄取限制,解读时需注意其对脑肿瘤表征的局限性。
局限性
- [18F]FDG PET在脑肿瘤应用中受高生理性灰质摄取限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PET using established and emerging molecularly targeted radiotracers has become integral to the evaluation and management of brain tumors, providing biologic information that complements conventional MRI to improve tumor characterization, treatment planning, and response assessment across a broad spectrum of neurooncologic diseases. Although [18F]FDG PET remains widely available, the technique is limited by high physiologic grey matter uptake. Somatostatin receptor (SSTR)-targeted PET, including DOTATATE PET, has greatly impacted meningioma evaluation through high tumor-to-background contrast, aiding radiotherapy planning and response assessment, along with patient selection for peptide receptor radionuclide therapy. SSTR-targeted PET has also been applied for paragangliomas, esthesioneuroblastomas, and other SSTR-positive tumors. Amino acid PET further improves the evaluation of gliomas and brain metastases, particularly for distinguishing tumor progression from treatment-related change. Emerging radiotracers targeting hormone receptors, hypoxia, tumor neovasculature, and the tumor microenvironment continue to expand the biologic information available from PET, while theranostic applications increasingly integrate molecular imaging with targeted therapy. This Special Series Review summarizes the current clinical roles of [18F]FDG, SSTR-targeted agents, amino acid tracers, and emerging radiotracers in the PET evaluation of brain tumors, highlighting the tracers' strengths and limitations. The article also explores evolving applications that are further integrating targeted PET into precision neurooncology.
引用
- Kuhn, Marulanda-Corzo, Gardella, et al. Molecular Brain Tumor Imaging Beyond [18F]FDG: Somatostatin Receptor PET, Amino Acid PET, and Emerging Applications-From the AJR Special Series on Molecular Imaging. AJR Am J Roentgenol. 2026. PMID: 42524738. doi:10.2214/AJR.26.35024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。